Imunon, Inc. (then Celsion Corporation) — Q1 2021 Form 10-Q
Business context and period: The filing covers the three months ended March 31, 2021. The registrant was a clinical-stage biotechnology company developing GEN-1 for ovarian cancer, ThermoDox for cancer indications, and the PLACCINE DNA vaccine platform. Revenue was primarily licensing revenue; the company reported no significant product revenue.
Key financial metrics
| Metric | Q1 2021 | Q1 2020 / comparison |
|---|---|---|
| Technology development and licensing revenue | $125,000 | $125,000; unchanged |
| Research and development expense | $2.57 million | $3.05 million; down 15.7% |
| General and administrative expense | $2.94 million | $1.84 million; up 59.7% |
| Total operating expenses | $5.51 million | $4.89 million; up 12.6% |
| Operating loss | $5.38 million | $4.77 million |
| Net loss | $5.69 million | $5.06 million |
| Basic and diluted loss per share | $0.09 | $0.20 |
| Operating cash used | $4.74 million | $4.98 million |
No meaningful operating margin is presented given the company’s minimal licensing revenue and substantial development costs. The lower reported loss per share in 2021 reflects a larger weighted-average share count, not improved net income.
At March 31, cash and cash equivalents were $37.76 million, short-term available-for-sale debt securities were $15.00 million, and the receivable from the sale of New Jersey net operating losses was $1.85 million. These totaled approximately $54.6 million. Current assets were $56.25 million, current liabilities $6.69 million, and working capital approximately $49.6 million. Total liabilities were $18.08 million. Notes payable, net of financing costs, totaled approximately $5.09 million; the Horizon loan is secured by substantially all assets other than intellectual property and has an April 2023 stated maturity.
Cash increased from $17.16 million at year-end 2020 to $37.76 million. Financing provided $40.46 million, including $38.94 million net proceeds from equity sales and $1.51 million from warrant exercises. Investing used $15.12 million, principally for purchases of short-term securities.
Material changes and developments
- R&D expense declined, primarily because OPTIMA trial costs fell after the trial was halted; GEN-1 and PLACCINE development spending increased.
- G&A expense rose mainly due to higher non-cash stock compensation, professional fees, and directors’ and officers’ insurance. Stock-based compensation was $1.58 million, versus $0.45 million a year earlier.
- Common shares issued increased to 75.0 million from 40.7 million at December 31, 2020, reflecting substantial equity financing. The filing reports 86.56 million shares outstanding as of May 13, 2021.
- The company completed a $35 million gross registered direct offering in January 2021. A further $15 million gross offering closed April 5, 2021, after quarter-end.
Outlook, risks, and unusual items
- Management expected operating losses to continue and stated that available resources, including the April offering and anticipated future New Jersey NOL sales, were expected to fund operations through the end of 2024. This estimate depends on assumptions; the company cautioned it could need funding sooner or in greater amounts. Further equity financing could dilute shareholders.
- The Phase III OPTIMA ThermoDox study crossed its prespecified futility boundary at the second interim analysis. After additional independent analyses, the company stopped following patients in February 2021 and froze the database at 185 deaths. Management said it would not pursue retrospective subgroup findings because of regulatory hurdles.
- GEN-1’s Phase II OVATION 2 study had enrolled approximately 34 of a planned 110 patients as of the February 2021 update. Among patients who had undergone surgery, R0 resections were reported for 12 of 15 GEN-1 patients (80%) and 7 of 12 control patients (58%). The study remained ongoing; these interim observations are not final efficacy results. The FDA granted GEN-1 Fast Track designation.
- PLACCINE was at an early research stage; the company had filed a provisional patent application and described potential vaccine applications, including COVID-19. The filing does not report clinical validation of a PLACCINE vaccine.
- COVID-19 had not significantly affected operations through the filing period, according to management, but could disrupt trials, enrollment, financing, and timelines.
- Two ThermoDox-related shareholder lawsuits remained unresolved. The company intended to defend them; at this early stage, it said any potential loss or range of loss could not be estimated. A separate shareholder action was settled in 2020, including $187,500 in plaintiff legal fees.
- A non-cash $151,000 quarterly expense increased the fair value of the ovarian-cancer earn-out liability to $7.17 million. The liability depends on milestone achievement and includes alternative payment terms.
Investor verification points
- Confirm cash runway assumptions and expected cash use against the stated end-of-2024 funding estimate, including the timing and net proceeds of post-quarter financing and NOL sales.
- Track share-count growth, future financing needs, and potential dilution; distinguish quarter-end shares from the 86.56 million shares reported outstanding on May 13.
- Review OVATION 2 enrollment, control-arm comparability, trial timing, and eventual prespecified efficacy results rather than relying on interim surgical outcomes.
- Assess the implications of OPTIMA’s futility outcome for ThermoDox and verify the scope and progress of investigator-sponsored studies.
- Monitor the unresolved securities and derivative lawsuits, the Horizon debt and covenants, and the contingent earn-out obligation.